Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2022-01-04 12:37 pm Sale | 13G | REGULUS THERAPEUTICS INC RGLS | VICTORY CAPITAL MANAGEMENT INC | 8,503,643 5.83% | -15,599 (-0.18%) | View |
| 2021-12-09 2:58 pm Purchase | 13D | REGULUS THERAPEUTICS INC RGLS | Growth Equity Opportunities V LLC | 14,582,521 9.99% | 12,530,067 (+610.49%) | View |
| 2021-03-08 11:05 am Purchase | 13G | REGULUS THERAPEUTICS INC RGLS | VICTORY CAPITAL MANAGEMENT INC | 8,519,242 12.73% | 8,519,242 (New Position) | View |
| 2021-02-12 7:23 pm Purchase | 13G | REGULUS THERAPEUTICS INC RGLS | BIOTECHNOLOGY VALUE FUND L P | 7,050,464 9.99% | 4,953,756 (+236.26%) | View |
| 2021-02-12 5:11 pm Unchanged | 13G | REGULUS THERAPEUTICS INC RGLS | Altium Capital Management LP | 3,229,780 6.8% | 0 (Unchanged) | View |
| 2021-02-12 4:15 pm Purchase | 13G | REGULUS THERAPEUTICS INC RGLS | EcoR1 Capital LLC | 3,650,080 5.4% | 1,327,436 (+57.15%) | View |
| 2020-12-09 5:13 pm Purchase | 13G | REGULUS THERAPEUTICS INC RGLS | Point72 Asset Management L.P. | 5,627,013 8.5% | 5,627,013 (New Position) | View |
| 2020-02-14 5:19 pm Purchase | 13G | REGULUS THERAPEUTICS INC RGLS | BIOTECHNOLOGY VALUE FUND L P | 2,096,708 9.99% | 1,044,768 (+99.32%) | View |
| 2020-02-14 1:51 pm Unchanged | 13G | REGULUS THERAPEUTICS INC RGLS | Altium Capital Management LP | 3,229,780 9.99% | 0 (Unchanged) | View |
| 2020-02-10 08:07 am Sale | 13G | REGULUS THERAPEUTICS INC RGLS | Sanofi SNY | 0 0% | -8,706,526 (Position Closed) | View |
| 2020-01-03 4:46 pm Purchase | 13G | REGULUS THERAPEUTICS INC RGLS | EcoR1 Capital LLC | 2,322,644 9.99% | 2,322,644 (New Position) | View |
| 2020-01-02 9:59 pm Purchase | 13D | REGULUS THERAPEUTICS INC RGLS | Sarissa Capital Management LP | 7,935,322 29.38% | 4,231,620 (+114.25%) | View |
| 2019-12-31 3:37 pm Purchase | 13G | REGULUS THERAPEUTICS INC RGLS | Altium Capital Management LP | 3,229,780 9.99% | 1,901,979 (+143.24%) | View |
| 2019-05-17 4:47 pm Purchase | 13D | REGULUS THERAPEUTICS INC RGLS | Sarissa Capital Management LP | 3,703,702 16.53% | 3,703,702 (New Position) | View |
| 2019-05-17 2:00 pm Purchase | 13G | REGULUS THERAPEUTICS INC RGLS | Altium Capital Management LP | 1,327,801 9.99% | 1,327,801 (New Position) | View |
| 2019-05-15 2:35 pm Sale | 13D | REGULUS THERAPEUTICS INC RGLS | Growth Equity Opportunities V LLC | 2,052,454 9.99% | -8,936,556 (-81.32%) | View |